| Nov 13 |
ORIC Pharmaceuticals GAAP EPS of -$0.49 in-line
|
| Nov 12 |
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
|
| Nov 4 |
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
|
| Nov 1 |
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 23 |
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Oct 15 |
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
|
| Oct 9 |
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 14 |
ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock
|
| Sep 6 |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 6 |
Stifel starts ORIC at buy, cites prostate cancer drug candidate
|
